long-lasting arrest murine polycystic kidney disease cdk inhibitor roscovitine
polycystic kidney diseases pkds primarily characterized growth fluid-filled cysts renal tubules leading end-stage renal disease- mutations pkd1 pkd2 genes lead autosomal dominant pkd adpkd slowly developing adult form autosomal recessive polycystic kidney disease results mutations pkhd1 gene affects newborn infants progresses rapidly effective treatment currently available pkd previously unrecognized site subcellular localization recently discovered proteins known disrupted pkd: primary cilia ciliary functions seem involved cell cycle regulation disruption proteins associated cilia centrioles may directly affect cell cycle proliferation resulting cystic disease- therefore reasoned dysregulated cell cycle may proximal cause cystogenesis intervention targeted point provide significant therapeutic benefit pkd show treatment cyclin-dependent kinase cdk inhibitor r-roscovitine indeed yield effective arrest cystic disease jck cpk mouse models pkd continuous daily administration drug required achieve efficacy pulse treatment provides robust long-lasting effect indicating potential clinical benefits lifelong therapy molecular studies mechanism action reveal effective cell-cycle arrest transcriptional inhibition attenuation apoptosis found roscovitine active cysts originating different parts nephron desirable feature treatment adpkd cysts form multiple nephron segments results indicate inhibition cdk new effective approach treatment pkd
